Teva Pharmaceutical Industries Ltd. Sept. 17 announced that the Food and Drug Administration has approved a new formulation of Treanda (bendamustine hydrochloride) injection.
This new liquid formulation removes the step of reconstituting lyophilized powder with sterile water prior to adding the medicine to the dilutent and administering to a patient, the Israel-based company said.
In 2008, the FDA approved Treanda for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia (CLL) 6 PLIR 1269, 11/7/08.
“By ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.